Wide Ranks

ELVN

Enliven Therapeutics, Inc.

25.41

Top Statistics
Market Cap 1 B Forward PE -11.29 Revenue Growth 0.00 %
Current Ratio 17.44 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 2.94 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 291 M Total Cash Per Share 6046.24 Total Debt
Total Debt To Equity Current Ratio 17.44 Book Value Per Share 5975.16
All Measures
Short Ratio 2973.00 % Message Board Id finmb_693128628 Shares Short Prior Month 6 M
Return On Equity -0.3098 City Boulder Uuid 467fab6a-c841-3428-aeda-27a7c3fd78b8
Previous Close 24.35 First Trade Date Epoch Utc 1 B Book Value 5975.16
Volume 168715 Price To Book 0.0043 Fifty Two Week Low 9.80
Total Cash Per Share 6046.24 Shares Short Previous Month Date 1 B Target Median Price 37.50
Max Age 86400 Recommendation Mean 1.14 Sand P52 Week Change 0.3133
Target Mean Price 37.17 Net Income To Common -85214000 Short Percent Of Float 0.3411
Implied Shares Outstanding 48 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 208630 Average Volume10days 208630 Total Cash 291 M
Next Fiscal Year End 1 B Held Percent Insiders 0.0639 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 24.35
Target Low Price 33.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 26.71
Open 24.45 Dividend Yield 0.00 % State CO
Return On Assets -0.2137 Time Zone Short Name EST Trailing Eps -1.89
Day Low 24.45 Address1 6200 Lookout Road Shares Outstanding 48 M
Price Hint 2 Target High Price 40.00 Website https://www.enliventherapeutics.com
52 Week Change 1.26 Average Volume 258409 Forward Eps -2.37
Recommendation Key strong_buy Compensation As Of Epoch Date 1 B Quick Ratio 1713.90 %
Is_sp_500 False Regular Market Day High 25.67 Profit Margins 0.00 %
Fifty Two Week High 30.03 Day High 25.67 Shares Short 7 M
Regular Market Open 24.45 Industry Key biotechnology Earnings Growth 0.00 %
Revenue Growth 0.00 % Shares Percent Shares Out 0.1446 Currency USD
Time Zone Full Name America/New_York Market Cap 1 B Is_nasdaq_100 False
Zip 80301 Quote Type EQUITY Industry Biotechnology
Long Name Enliven Therapeutics, Inc. Regular Market Day Low 24.45 Held Percent Institutions 0.9875
Current Price 25.41 Enterprise To Ebitda 2.94 Financial Currency USD
Current Ratio 17.44 Industry Disp Biotechnology Number Of Analyst Opinions 6
Country United States Float Shares 25525 Two Hundred Day Average 22.26
Enterprise Value -290607520 Forward PE -11.29 Regular Market Volume 168715
Ebitda -98775000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.

The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

The company is headquartered in Boulder, Colorado.